Aakaar Medical (AAKAAR)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹56.50, Aakaar Medical is a small personal-care company with a market cap of just ₹90 crore. The trailing P/E of 14.90 looks reasonable, but I have learned that a cheap multiple can be a value trap when earnings deteriorate. The latest quarter reports sales of ₹25 crore and a net loss of ₹1 crore. That is a serious warning sign. Sales growth is zero, profit growth is zero, and the Piotroski F-score is only 3 out of 9. These are not the numbers of a healthy compounding business. I also cannot calculate a conventional margin of safety because book value and debt-equity data are not available. In Graham's language, the absence of data is not comfort; it is a reason to demand more information. Promoter holding is high at 67.05%, which at least suggests owner interests are aligned with minority investors. The 26.66% ROCE is genuinely impressive, if it is sustainable, but current profitability is not proving it. There is no dividend yield, so I am not being paid to wait. The stock has fallen from ₹84.95 to ₹56.50, but a falling price is not automatically an opportunity. For a value investor, the question is whether the underlying business can generate reliable future profits. With a loss in the latest quarter and an F-score of 3, this looks more like a turnaround situation than a stable slow grower. I would want to see several quarters of positive net profit, clearer revenue traction, and full balance-sheet disclosure before committing capital. Until then, the prudent stance is to observe, not own.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer